Mohandas Narla, head of the laboratory of red cell physiology at New York Blood Center Enterprises, began his term as president of the American Society of Hematology. He will serve a year-long term through December 2024.
Kite announced findings from three new analyses for Yescarta (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory large B-cell lymphoma, which were presented at 66th American Society of Hematology annual meeting.
